CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma

BACKGROUND: Because of the high incidence and poor prognoses of lung adenocarcinoma (LUAD), it is essential to identify cost-effective treatment options and accurate and reliable prognostic biomarkers. CDCA4 upregulation has been identified in many cancers. However, the prognostic importance of CDCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Jianlong, Chen, Fengyu, Ouyang, Bin, Li, Xiuying, Zhang, Weidong, Gao, Xinglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520321/
https://www.ncbi.nlm.nih.gov/pubmed/36185189
http://dx.doi.org/10.3389/fonc.2022.865756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520321/
https://www.ncbi.nlm.nih.gov/pubmed/36185189
http://dx.doi.org/10.3389/fonc.2022.865756

Ejemplares similares